David Johnson General Information

Description

Mr. David Johnson is an Angel Investor. He is a Co-Founder and serves as Chief Executive Officer and Board Member at GigaMune. He also serves as Entrepreneur in Residence at Illumina Ventures. He is developing a full stack of technologies for the discovery of anti-tumor payloads with petabase-scale sequence search and high-throughput screening, novel viruses for payload delivery, and new enzymes for genome editing. Previously, he brought GigaGen from concept to clinic. He led the negotiation and sale of the company to Grifols for a company valuation of $142.9 million (with potential for further product-related earnout) in March 2021. Also, he was among the founding members and COO of Natera (NASDAQ: NTRA). Prior to Natera, he was the ENCODE Project Director at the Stanford Human Genome Center. He is an inventor, entrepreneur, and expert in genomics with a track record of bringing new medical technologies to the clinic and the market. He holds a BS in Biology from Duke University, a Ph.D. in Genetics from Stanford University, and an MBA from the Haas School of Business at the University of California, Berkeley.